ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Azo‐PROTAC‐4C demonstrated that it can induce the CRBN‐dependent degradation of BCR‐ABL, thereby selectively inhibiting the cellular proliferation of CML cells with nanomolar potency (IC50 = 68 nM).88